MIT researchers are now turning the prolific Boltz series of models into a software company that promotes open science for AI-guided therapeutics.

Researchers from the Massachusetts Institute of Technology (MIT) Jameel Clinic for Machine Learning in Health have announced the open-source release of Boltz-2, which now predicts molecular binding ...

In the pharmaceutical discovery process, understanding a drug’s residence time—the duration a molecule remains bound to its ...

Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at ...

The year 2025 marked a major leap for AI in health care, with breakthroughs in drug discovery, diagnostics, genomics and ...

Drug discovery is a complex field that demands rigorous testing and comprehensive data analysis to ensure potential drug candidates can advance to clinical trials. One critical step is screening for ...

Drug discovery is a costly and time-intensive process, with binding free energy calculations between the potential drug ...

Researchers at the Massachusetts Institute of Technology and Recursion Pharmaceuticals Inc. have released an open-source AI model that can predict the binding strength of small molecules as well as ...

The ability to alter proteins to refine control over binding affinity and specificity can create tailored therapeutics with reduced side effects, highly sensitive diagnostic tools, efficient ...